Displaying 13 - 24 of 38
Metabolism, Alcohol & Toxicity
3

Novo Nordisk: Navigating MASH patient care - EASL Congress 2024

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Displaying 13 - 24 of 38